22:14 , Aug 15, 2018 |  BC Extra  |  Company News

Management tracks: Karuna, VBI Vaccines

Neurology company Karuna Pharmaceuticals Inc. (Boston, Mass.) named Chairman Steven Paul as CEO. He replaces co-founder Andrew Miller, who became COO. Paul, a neuroscientist, was a longtime employee at Eli Lilly and Co. (NYSE:LLY) and...
23:07 , Jun 5, 2018 |  BC Extra  |  Company News

Management tracks: Sarepta, Gilead

Neuromuscular disease company Sarepta Therapeutics Inc. (NASDAQ:SRPT) hired Louise Rodino-Klapac as VP of gene therapy at its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc. (New...
00:38 , Apr 1, 2017 |  BC Extra  |  Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
21:09 , Jan 27, 2017 |  BC Week In Review  |  Company News

InVivo, PixarBio deal

PixarBio withdrew its offer to acquire InVivo. PixarBio said it expects an FDA decision on its non-opiate morphine replacement therapy by early 2019. Earlier this year, PixarBio proposed to acquire InVivo for $100 million in...
19:54 , Jan 13, 2017 |  BC Week In Review  |  Company News

InVivo, PixarBio deal

PixarBio proposed to acquire InVivo for $100 million in stock. The combined company would be renamed Reynolds Therapeutics Corp. and focus on pain, spinal cord injury, adaptive technologies, epilepsy and Parkinson's disease. According to PixarBio,...
07:00 , Aug 8, 2016 |  BC Extra  |  Financial News

Pain play PixarBio looks to raise up to $30M

Pain company PixarBio Corp. (Medford, Mass.) said it is in the process of merging with an undisclosed public entity and plans to raise $20-$30 million in a PIPE. The company expects to be publicly traded...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Fundamental reset

Steve Edelson, Senior Editor   After three months of carnage, buysiders acknowledge their conservative prediction of biotech keeping pace with the broader markets is unlikely to occur this year. Instead, investors are looking for the...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Financial News

InVivo Therapeutics completes follow-on

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), Cambridge, Mass.   Business: Neurology   Date completed: 2016-03-15   Type: Follow-on   Raised: $28 million   Units: 3.7 million   Price: $7.50 (unit)   Shares after offering: 31.3 million...
00:38 , Jun 13, 2015 |  BC Extra  |  Company News

Management tracks

NIH said Deputy Director of Extramural Research Sally Rockey will resign. She will become director of the Foundation for Food and Agriculture Research. NIH also named Walter Koroshetz director of the National Institute of Neurological...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Financial News

InVivo Therapeutics completes direct public offering

InVivo Therapeutics Holdings Corp. (OTCQB:NVIV), Cambridge, Mass.   Business: Neurology   Date completed: 2015-01-29   Type: Direct public offering   Raised: $12 million   Shares: 8 million   Price: $1.50   Shares after offering: 101.5...